Intellia Therapeutics, Inc. - מכפיל שווי פעילות להכנסות NTLA

Intellia Therapeutics (NTLA) is developing CRISPR-based gene therapies to combat rare pathologies. The historical EV/Sales level demonstrates the dynamics of the business's market premium, where 20651.16 represents the most recent metric reading. The company outsources production and testing to third-party contractors while retaining patent ownership. The absence of current sales is offset by partner capital and the relevance of its technological platforms.
intelliatx.com - פילוחים אנליטיים ומדדי מפתח (NTLA)

The metric is calculated as the ratio of enterprise value (EV) to sales, excluding the impact of debt load. It determines the market premium paid for every dollar of revenue, reflecting investment expectations for future cash flows. For Intellia Therapeutics (NTLA), this indicator is driven by the high value of CRISPR patents and R&D expenditures. Strict FDA oversight makes the asset extremely sensitive to any changes. The current enterprise value-to-revenue level signals the extent of the premium for technological leadership.